Atherosclerosis
Volume 204, Issue 1 , Pages 66-72, May 2009

A novel antioxidant 3,7-dihydroxy-isoflav-3-ene (DHIF) inhibits neointimal hyperplasia after vessel injury attenuating reactive oxygen species and nuclear factor-κB signaling

  • Peter Kanellakis

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
  • ,
  • Giovanna Pomilio

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
  • ,
  • Catherine Walker

      Affiliations

    • Novogen Pty Ltd, North Ryde, NSW, Australia
  • ,
  • Alan Husband

      Affiliations

    • Novogen Pty Ltd, North Ryde, NSW, Australia
  • ,
  • Jiu Li Huang

      Affiliations

    • Novogen Pty Ltd, North Ryde, NSW, Australia
  • ,
  • Paul Nestel

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
  • ,
  • Alex Agrotis

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
  • ,
  • Alex Bobik

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
    • Corresponding Author InformationCorresponding author at: Cell Biology Laboratory, Baker Heart Research Institute, PO Box 6492, St Kilda Road Central, Melbourne, Victoria, Australia. Tel.: +61 3 8532 1190; fax: +61 3 8532 1100.

Received 19 March 2008; received in revised form 29 August 2008; accepted 1 September 2008. published online 20 October 2008.

Abstract 

Reactive oxygen species (ROS) contribute to neointimal smooth muscle proliferation by yet to be defined mechanisms. We examined the effects of a novel isoflavone 3,7-dihydroxy-isoflav-3-ene (DHIF) on development of neointimal lesions in relation to ROS elevations and cell signaling in injured arteries. Carotid arteries of rabbits treated with vehicle or DHIF were injured with a balloon catheter and effects on proliferation, apoptosis, vessel structure, ROS, NF-κB activation, cyclooxygenase and gene expression examined. Seven days after injury proliferating neointimal cells were reduced by 35% (P<0.05) whilst medial cell proliferation was attenuated by 16% (P<0.05). ROS levels were elevated fourfold in injured arteries of vehicle-treated rabbits. Treatment with DHIF prevented this elevation (P<0.05). Also, NF-κB was activated in neointimal cells from vehicle-treated rabbits, demonstrated by nuclear accumulation of NF-κB-p65. DHIF not only attenuated its nuclear accumulation but also suppressed NF-κB-p65 expression in neointimal cells. This was accompanied by a doubling of apoptotic cell numbers (P<0.05). Expression of cyclooxygenases Cox-1 and Cox-2 were also attenuated, by 74% and 50%, respectively (P<0.05), as was MCP-1. The antiproliferative effects of DHIF persisted at 14 days, and 28 days after injury neointima growth was attenuated by 50% (P<0.05). Thus, ROS stimulates neointima growth via mechanisms involving NF-κB activation, cyclooxygenases and MCP-1. DHIF’s ability to attenuate NF-κB activation suggests that it may not only be useful in preventing restenosis but also in attenuating atherosclerosis.

Keywords: Vessel injury, Superoxide, Neointima, NF-κB, Cyclooxygenase

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0021-9150(08)00624-2

doi:10.1016/j.atherosclerosis.2008.09.005

Atherosclerosis
Volume 204, Issue 1 , Pages 66-72, May 2009